Merocyanine derivatives as theranostic agents for cognitive improvement and real-time imaging of amyloid-β in APP/PS1 transgenic mice.
The probe D4 shows promise for both imaging and cognitive improvement in a mouse model of Alzheimer's Disease, but further research is needed to confirm its efficacy in humans.
Where it sits
this study against the rest of the lixisenatide corpusSummary and findings
The study evaluated the effects of the merocyanine derivative D4 on amyloid-β in APP/PS1 transgenic mice. The probe demonstrated an inhibition rate of 89.5% for Aβ aggregation and improved cognitive ability after intravenous administration of 0.5 mg/kg for 15 days. The findings indicate potential for both imaging and treatment of Alzheimer's Disease.
Abstract
Amyloid-β (Aβ) is widely recognized as a biomarker for the diagnosis and treatment of Alzheimer's Disease (AD). In our previous work, a series of merocyanine fluorescent probes were designed, synthesized and evaluated for the imaging of Aβ plaques. Here, we further identified the representative probe D4, which not only demonstrates the characteristics of a highly sensitive fluorescent probe for real-time imaging of Aβ content in the brain of APP/PS1 mice, but also exhibited the ability to treat AD, including inhibition of Aβ aggregation (inhibition rate: 89.5%), antioxidant activity (3.4 times that of Trolox); AChE inhibitory activity (IC<sub>50</sub> = 0.5 ± 0.0 μM) and the capacity to cross the BBB (P<sub>e</sub> = 8.6 ± 0.7). Additionally, D4 dramatically attenuates Aβ-induced SH-SY5Y cell death by preventing the generation of ROS, and intravenous administration of 0.5 mg/kg D4 for 15 days significantly improved the cognitive ability of 7-month-old APP/PS1 mice by protecting hippocampal and cortex neurons from necrosis, attenuating oxidative stress in the hippocampus and cortex, and reducing Aβ burden deposition. These findings strongly suggest that D4 owns a high theranostic potential for treating AD.